Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair

BACKGROUND: We evaluated the impact of 3 months of mFOLFOX6 adjuvant chemotherapy or surgery alone in comparison with 6 months of mFOLFOX6 on disease-free survival (DFS) in deficient mismatch repair (dMMR) colon cancer (CC) patients. METHODS: This retrospective study identified a cohort of patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Hu, Huabin, Wu, Zehua, Wang, Chao, Huang, Yan, Zhang, Jianwei, Cai, Yue, Xie, Xiaoyu, Li, Jianxia, Shen, Cailu, Li, Weiwei, Ling, Jiayu, Xu, Xuehu, Deng, Yanhong
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7747753/
https://ncbi.nlm.nih.gov/pubmed/33344234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.579478
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados